Sirtris Pharmaceuticals Enters Collaborative Study Testing New Chemical Entities and Clinical Drug Candidate In Multiple Models
February 21 2008 - 8:00AM
Business Wire
Sirtris Pharmaceuticals (NASDAQ: SIRT), a biopharmaceutical company
focused on discovering and developing small molecule drugs to treat
diseases of aging, announced today that it will collaborate with
the National Cancer Institute to test the anti-cancer impact of
Sirtris� SIRT1 enzyme activators in numerous models of cancer. �By
providing the resources for this study, the National Cancer
Institute is accelerating the testing of our compounds in both
solid and hematological models of cancer,� said Sirtris
Pharmaceuticals Chief Executive Officer and Vice Chair Christoph
Westphal, MD, PhD. �Cancer is the second leading cause of
age-related mortality, and this study will advance our
understanding of SIRT1 activation and its potential anti-cancer
properties.� The study will include SRT501, a proprietary
formulation of resveratrol, and multiple compounds from different
chemical classes of Sirtris� new chemical entities, which are 1000
times more potent than resveratrol in in-vitro studies. All of the
compounds activate SIRT1, an enzyme that has been shown to have
anti-cancer properties in previous preclinical testing. �I am proud
to be teaming again with Tom Sayers, the study�s lead investigator
at the National Cancer Institute,� said Peter Elliott, Senior Vice
President and Head of Development at Sirtris Pharmaceuticals.
�Several years ago Tom and I worked successfully together on the
development of the anti-cancer drug Velcade, and now we are
exploring an exciting new opportunity for targeting cancers using
SIRT1 activators.� The National Cancer Institute will test the
compounds in well-established cancer cell lines which were
previously used in the development of novel and existing
chemo-therapeutics. The cell lines to be tested include some of the
most common cancer types. The program will also test Sirtris�
compounds using in-vivo mouse tumor models to determine if the
compounds reduce or limit the growth of the tumor cells. Previous
studies have shown that calorie restriction�a method which has been
shown to increase SIRT1 activation�can exert strong tumor
suppressor effects in mammals and increase lifespan in organisms.
Through direct activation of the SIRT1 enzyme with Sirtris�
compounds, researchers in this study will be able explore the
enzyme�s role in tumor suppression along multiple pathways. About
Sirtris Pharmaceuticals Sirtris Pharmaceuticals is a
biopharmaceutical company focused on discovering and developing
proprietary, orally available, small molecule drugs with the
potential to treat diseases associated with aging, including
metabolic diseases such as Type 2 Diabetes. Our drug candidates are
designed to mimic certain beneficial health effects of calorie
restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
the Company believes control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
include, but are not limited to, the potential therapeutic effects
of SIRT1 activators, including SRT501 and Sirtris� NCEs for
diseases of aging, such as Type 2 Diabetes and cancer; the progress
and results of pre-clinical studies of SIRT1 activators; and the
potential of sirtuin modulators to receive regulatory approval.
These forward-looking statements about future expectations, plans
and prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack
of results that would provide a basis for predicting whether any of
the Company's product candidates will be safe or effective, or
receive regulatory approval, the possibility that results of
pre-clinical studies are not necessarily predictive of clinical
trial results, the Company's potential inability to initiate and
complete pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company's product candidates
has received regulatory approvals, the potential inability of the
Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024